Skip to main content
. 2006 Dec 11;6:285. doi: 10.1186/1471-2407-6-285

Table 3.

Response Rate Data

Cilengitide + Gemcitabine n = 46 Gemcitabine n = 43

No. patients % No. patients %
Complete response 0 0% 1 2%
Partial response 8 17% 5 12%
Stable disease 17 37% 18 42%
Progressive disease 12 26% 10 23%
Missing/not assessable 9 20% 9 21%

Response rate 8 17% 6 14%
Tumor growth control 25 54% 24 56%